GV.PA Genomic Vision SA EURONEXT pre-market 26 Feb 2026: High volume, key impact
GV.PA stock is trading at €0.0018 pre-market on EURONEXT after a +5.88% intraday move and unusually high volume of 38,489,238 shares. The spike puts Genomic Vision SA (GV.PA) at the top of most-active lists for Europe healthcare micro-caps. Volume is 2.71x the average, suggesting short-term liquidity and heightened trader interest. We summarise what the numbers mean for valuation, catalysts and risk ahead of next news and the company’s positioning in diagnostics.
GV.PA stock quick snapshot
Genomic Vision SA (GV.PA) trades on EURONEXT in Europe at €0.0018 with market cap €693,191 and shares outstanding 385,105,984. Day range is €0.0015–€0.0020, year range €0.0014–€0.094. Current volume 38,489,238 vs avg 14,217,513 signals heavy intra-day activity. The company operates in Healthcare, Medical – Diagnostics & Research, focused on molecular combing and single DNA detection tools.
Financials and valuation: metrics to watch
GV.PA shows trailing EPS -0.11 and a negative P/E around -0.02, reflecting recurring losses. Price-to-Sales is 0.47 and EV/Sales is 1.60, while cash per share is 0.0056. CurrentRatio is 0.91, and enterprise value €2,369,191 indicates leverage relative to tiny market cap. These ratios show a high-risk small-cap with limited liquidity and negative profitability.
Technical and trading activity: most-active dynamics
Price averages are depressed: 50-day around €0.00484 and 200-day around €0.013997, both well above the current price, confirming a long downtrend. RelVolume is 2.71, and volume spikes often accompany news searches or speculative trading in micro-caps. Day buyers may test the €0.0020 high; failure below €0.0015 could increase selling pressure given thin order books.
Meyka grade and GV.PA stock forecast
Meyka AI rates GV.PA with a score out of 100: 62.66 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a 12‑month target of €0.0050, compared with the current €0.0018, implying +177.78% upside. Forecasts are model-based projections and not guarantees.
Catalysts, risks and sector context for GV.PA stock
Primary catalysts include partnership rollouts, commercialization of FiberVision scanners, and any positive clinical validation. Sector tailwinds: Healthcare in Europe shows a 1Y performance of 2.81% for the narrower healthcare bucket and strong institutional interest in diagnostics. Key risks are extremely low liquidity, recurring losses, long inventory cycles, and reliance on a small number of commercial agreements.
Trading strategy: most-active angle for GV.PA stock
Given the ‘most active’ status, short-term traders should size positions small and use limit orders to manage thin spreads. Watch intraday resistance near €0.0020 and support at €0.0014–€0.0015. For longer-term investors, focus on fundamental improvement, cash runway and execution on alliances before increasing exposure. See company page on Meyka for live tools and alerts: Genomic Vision (GV.PA) on Meyka.
Final Thoughts
GV.PA stock is currently a high-risk, high-volatility micro-cap trading at €0.0018 pre-market on EURONEXT with heavy volume of 38,489,238 shares. Financials show negative EPS -0.11, low cash per share and a weak current ratio 0.91, so fundamentals do not yet support a durable recovery. Meyka AI rates GV.PA 62.66 out of 100 (Grade B, HOLD), reflecting sector comparisons and growth metrics. Meyka AI’s forecast model projects €0.0050 in 12 months, an implied +177.78% from today, but forecasts are model-based projections and not guarantees. Short-term traders can exploit the liquidity spike but should use tight risk controls. Long-term investors should wait for clearer revenue momentum, improved cash metrics and tangible product commercialisation before increasing position size.
FAQs
What is the current price and volume for GV.PA stock?
GV.PA stock is trading pre-market at €0.0018 with volume 38,489,238 shares, about 2.71x the 50-day average. Day range is €0.0015–€0.0020 and previous close was €0.0017.
What grade does Meyka AI give GV.PA stock and why?
Meyka AI rates GV.PA 62.66/100 (Grade B: HOLD). The grade uses S&P 500 and sector comparisons, financial growth, key metrics, forecasts and analyst data. These grades are informational and not financial advice.
What are the main risks for investors in GV.PA stock?
Main risks include very low liquidity, negative earnings (EPS -0.11), a weak current ratio 0.91, reliance on a few commercial partners and long inventory cycles. Small-cap moves can be sudden and high-loss if not sized correctly.
What price target does Meyka AI forecast for GV.PA stock?
Meyka AI’s forecast model projects a 12-month target of €0.0050, compared with the current €0.0018, implying +177.78% upside. Forecasts are model-based projections and not guarantees.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.